Le Lézard
Classified in: Health, Science and technology

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


SEATTLE, Feb. 7, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on February 7, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received options to purchase an aggregate of 102,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO® is a registered trademark of CTI BioPharma Corp.

Investor Relations and Media Contacts:

Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com  

(PRNewsfoto/CTI BioPharma Corp.)

SOURCE CTI BioPharma Corp.


These press releases may also interest you

at 04:25
Digiasia Bios announced its new cooperation with PT Jabar Telematika (JT Digital), one of West Java Regional Owned Enterprise (BUMD Jawa Barat). The agreement was signed by the Chief Operating Officer (COO) of Digiasia Bios, Hermansyah Haryono and...

at 04:05
Zero VFX ("Zero") and Mavericks VFX ("Mavericks") are announcing the formation of a new visual effects group through a merger enabled by the investment of Arenova Capital ("Arenova"), a growth investment firm dedicated to partnering with...

at 04:05
Forrester today announced the full conference agenda for its CX EMEA event being held in London and digitally on 10?11 May 2023. At a time when consumer brands are bracing for strong, macro-level headwinds, including inflation, talent shortages, and...

at 04:00
March 21, 2023 - Cloud Ratings has initiated research coverage of the Direct Mail Automation...

at 04:00
Ontotext, the leading global provider of enterprise knowledge graph (EKG) technology and semantic database engines, today announced the immediate availability of Ontotext Metadata Studio version 3.2.  This sophisticated metadata management and...

at 04:00
Small to large business owners are happy to know that printing and designing blank checks in-house offers great savings when utilizing ezCheckprinting check writer from halfpricesoft.com. This new version includes an...



News published on 7 february 2023 at 20:28 and distributed by: